Biopharmaceutical company
Appears in 1 story
Developer of remlifanserin; planning phase 3 amendments
Acadia Pharmaceuticals said its experimental Alzheimer's psychosis treatment missed the primary goal of a phase 2 trial. The company is advancing remlifanserin to phase 3 anyway, betting a refined study design can turn a near-miss into a win.
Updated 2 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
